US OptionsDetailed Quotes
AAPL241213P155000
- 0.01
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.01Open0.01Pre Close0 Volume26 Open Interest155.00Strike Price0.00Turnover5866.82%IV37.54%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0009Delta0.0001Gamma24813.00Leverage Ratio-18.8831Theta0.0000Rho-22.59Eff Leverage0.0000Vega
Apple Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
3
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
1
$Apple (AAPL.US)$
👇🏻👁
Apple went public 44 years ago—what your $10,000 investment would be worth today" data-critical="true
👇🏻👁
Apple went public 44 years ago—what your $10,000 investment would be worth today" data-critical="true
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Apple (AAPL.US)$ $Invesco QQQ Trust (QQQ.US)$ bearish bearish everywhere, crossing down on four hours on every indicator..... From way up high ![]()
2
3
$Apple (AAPL.US)$ something is not right caution
5
1
It's finally Friday, December 13th, and the market fell from a climb this morning into a light fall. Here are stories you may have missed moving markets today:
$Broadcom (AVGO.US)$ climbed upwards of 20%, the highest reaching percentage climber on the S&P 500 after the firm reported earnings that beat estimates Thursday, with revenue that climbed 51% from a year ago. AAI revenue for the fiscal year climbed 220%. The climb sent the stock to over $1T in ma...
$Broadcom (AVGO.US)$ climbed upwards of 20%, the highest reaching percentage climber on the S&P 500 after the firm reported earnings that beat estimates Thursday, with revenue that climbed 51% from a year ago. AAI revenue for the fiscal year climbed 220%. The climb sent the stock to over $1T in ma...
13
1
Stock futures were higher premarket after markets gave back some recent gains in the previous session. Tech stocks seem to be regaining strength. Let’s see if Nasdaq can close back above the milestone level of 20,000.
Meanwhile, sticky and persistent inflation could force Fed to re-consider their rate cut campaign next year. But that’s for 2025. Next week’s FOMC meeting will likely see the Fed cutting interest rate by 25 basis points again – probably setting the market up for ...
Meanwhile, sticky and persistent inflation could force Fed to re-consider their rate cut campaign next year. But that’s for 2025. Next week’s FOMC meeting will likely see the Fed cutting interest rate by 25 basis points again – probably setting the market up for ...
From YouTube
6
1
Volume and turnover are two important indicators in the financial market, which reflect the degree of trading activities and the situation of capital flow in the market. The primary factor determining whether a stock is good or not lies in its volume and turnover.
What is volume?
Volume represents the quantity of securities traded within a specific period of time. High volume usually indicates that market particip...
What is volume?
Volume represents the quantity of securities traded within a specific period of time. High volume usually indicates that market particip...
15
1
2
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.